SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and ...

bluebird bio's stock has fallen significantly from its 52-week high after its gene therapy results disappointed some investors. Investors seem to be misinterpreting the data presented at the recent ...

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have successfully completed the tender offer for bluebird bio, Inc.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public ...

(RTTNews) - Investment firm Carlyle Group Inc. (CG), along with SK Capital Partners, LP and Beacon Parent Holdings, L.P., on Friday announced that the proposed acquisition of bluebird bio, Inc. (BLUE) ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. CASE ALLEGATIONS: bluebird bio is a biotechnology ...

With bluebird's and Alnylam's shares currently trading close to their 52-week lows, according to S&P Global Market Intelligence, let's consider which stock has the better chance of recapturing some of ...

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...